Feed 4AB.DU
4A

AbbVie Inc.

4AB.DU · DUS

231.30 € +0.09% (+0.20 €)
1M +5.86%
Market Cap $459.9B
P/E Ratio 72.76x
Div. Yield 2.54%
ROE -

Bulios Fair Price

210.02 €

9.2% downside

Current Price

231.3 €

Undervalued Fair Value Overvalued

According to Bulios Fair Price, 4AB.DU is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Strong
8/9
Valuation
27 /100
Expensive
P/E 72.76x
P/FCF 24.10x
EV/EBITDA 19.65x
Growth
11 /100
Declining
EPS growth 28.93%
FCF growth 9.76%
Rev. growth 1.75%
Profitability
93 /100
Strong
Gross margin 86.98%
FCF margin 29.66%
Net margin 9.82%
Quality
69 /100
Excellent
ROIC 17.14%
Asset turnover 0.48x
ROA 4.67%
Debt
48 /100
Moderate
Current ratio 0.81x
Net debt/EBITDA 2.41x
Int. coverage 5.49x
Stability
65 /100
Moderate
Beta 0.01x
Profitable years 6
Rev. volatility 7.66%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about 4AB.DU
Online

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Robert A. Michael

Employees

57,000

Headquarters

North Chicago

Upcoming events

15 OCT

Ex-Dividend

Ex-dividend date

10d
30 OCT

Earnings

Upcoming earnings report

25d
16 NOV

Dividend Payment

Payment date

42d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.